Core Insights - CytoDyn Inc. has reached an agreement in principle to resolve a securities class action lawsuit filed in March 2021, pending final court approval [1][2][3] Group 1: Legal Resolution - The settlement agreement was reached on November 23, 2025, and is subject to final court approval [2] - The resolution is expected to provide clarity and finality for stakeholders, including stockholders and potential pharmaceutical partners [3] Group 2: Company Focus and Development - CytoDyn is focused on advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, with applications in metastatic triple-negative breast cancer and colorectal cancer [1][4] - The company aims to move forward with its clinical development programs following the resolution of the lawsuit, emphasizing the importance of closure for stockholders [3] - There is optimism regarding leronlimab's potential, supported by ongoing Phase II studies and progress in the Expanded Access Program [3]